Biogen Inc. (BIIB) Earnings History
Earnings Pressure37 years of earnings data (1989–2025) · 5-year EPS trend is negative
Loading earnings history...
Biogen Inc. (BIIB) Earnings Overview
As of June 21, 2026, Biogen Inc. (BIIB) reported trailing twelve-month net income of $1.37B, reflecting -21.1% year-over-year growth. The company earned $9.25 per diluted share over the past four quarters, with a net profit margin of 13.2%.
Looking at the long-term picture, BIIB's 5-year EPS compound annual growth rate (CAGR) stands at -18.7%, signaling declining earnings. The company achieved its highest annual net income of $5.89B in fiscal 2019.
Biogen Inc. maintains positive profitability with a gross margin of 70.5%, operating margin of 19.1%, and net margin of 13.2%. The company continues to generate positive earnings from operations. View revenue history →
Compared to peers including REGN ($4.42B net income, 31.4% margin), VRTX ($4.34B net income, 32.7% margin), BMRN ($269M net income, 10.8% margin), BIIB has room to improve margins relative to the peer group. Compare BIIB vs REGN →
BIIB Earnings vs Peers
Earnings metrics vs comparable public companies
BIIB Historical Earnings Data (1989–2025)
37 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $1.29B | -20.8% | $1.88B | $8.83 | 13.2% | 19.1% |
| 2024 | $1.63B | +40.6% | $2.49B | $11.19 | 16.9% | 25.7% |
| 2023 | $1.16B | -61.9% | $2.10B | $7.97 | 11.8% | 21.3% |
| 2022 | $3.05B | +95.8% | $2.89B | $20.87 | 29.9% | 28.4% |
| 2021 | $1.56B | -61.1% | $2.79B | $10.40 | 14.2% | 25.4% |
| 2020 | $4.00B | -32.1% | $4.59B | $24.80 | 29.8% | 34.2% |
| 2019 | $5.89B | +32.9% | $7.04B | $31.42 | 41.0% | 49.0% |
| 2018 | $4.43B | +74.5% | $5.89B | $21.58 | 32.9% | 43.8% |
| 2017 | $2.54B | -31.4% | $5.35B | $11.92 | 20.7% | 43.6% |
| 2016 | $3.70B | +4.4% | $5.15B | $16.93 | 32.3% | 45.0% |
| 2015 | $3.55B | +20.9% | $4.89B | $15.34 | 33.0% | 45.4% |
| 2014 | $2.93B | +57.6% | $3.97B | $12.37 | 30.2% | 40.9% |
| 2013 | $1.86B | +34.9% | $2.52B | $7.81 | 26.9% | 36.3% |
| 2012 | $1.38B | +11.8% | $1.84B | $5.76 | 25.0% | 33.3% |
| 2011 | $1.23B | +22.8% | $1.72B | $5.04 | 24.5% | 34.2% |
| 2010 | $1.01B | +3.6% | $1.25B | $3.94 | 21.3% | 26.5% |
| 2009 | $970M | +23.9% | $1.30B | $3.35 | 22.2% | 29.6% |
| 2008 | $783M | +22.7% | $1.21B | $2.65 | 19.1% | 29.6% |
| 2007 | $638M | +193.4% | $780M | $1.99 | 20.1% | 24.6% |
| 2006 | $218M | +35.3% | $440M | $0.63 | 8.1% | 16.4% |
| 2005 | $161M | +540.6% | $236M | $0.47 | 9.4% | 13.8% |
| 2004 | $25M | +102.9% | $43M | $0.07 | 1.6% | 2.7% |
| 2003 | -$875M | -690.9% | -$870M | $-2.62 | -470.1% | -467.2% |
| 2002 | $148M | -45.7% | $214M | $0.50 | 36.6% | 52.9% |
| 2001 | $273M | -18.3% | $360M | $0.68 | 26.2% | 34.6% |
| 2000 | $334M | +51.3% | $328M | $0.72 | 36.0% | 35.5% |
| 1999 | $220M | +58.9% | $316M | $0.47 | 27.7% | 39.8% |
| 1998 | $139M | +55.5% | $191M | $0.15 | 24.9% | 34.2% |
| 1997 | $89M | +120.0% | $149M | $0.10 | 20.5% | 34.3% |
| 1996 | $41M | +616.1% | $41M | $0.04 | 14.6% | 14.7% |
| 1995 | $6M | +215.6% | $7M | $0.01 | 3.7% | 4.9% |
| 1994 | -$5M | -115.1% | -$2M | $-0.01 | -3.1% | -1.2% |
| 1993 | $32M | -15.4% | $22M | $0.04 | 23.8% | 15.9% |
| 1992 | $38M | +431.9% | $29M | $0.04 | 31.0% | 23.1% |
| 1991 | $7M | -6.5% | -$1M | $0.01 | 11.7% | -2.1% |
| 1990 | $8M | +140.6% | $800,000 | $0.00 | 15.4% | 1.6% |
| 1989 | $3M | - | -$9M | $0.01 | 11.2% | -31.6% |
Download Data
Export BIIB earnings history in CSV or JSON format
Free sign-in required to download data
Full Stock Analysis
Deep dive into BIIB consensus models and risk factors.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
37+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
BIIB — Frequently Asked Questions
Quick answers to the most common questions about buying BIIB stock.
What is BIIB earnings per share (EPS)?
BIIB trailing twelve-month (TTM) diluted EPS is $9.25, reflecting -21.1% year-over-year growth. The 5-year EPS CAGR is -18.7%. Complete EPS history from 1989 to 2025 is available in the table on this page.
What is Biogen Inc.'s net income?
Biogen Inc. (BIIB) trailing twelve-month net income is $1.4B as of 2025. Earnings declined -21.1% year-over-year. Biogen Inc. has been profitable for 22 consecutive years.
Is BIIB profitable?
Yes, BIIB is profitable with a TTM net income of $1.4B and a net profit margin of +13.2%. Biogen Inc. has generated profits for 22 consecutive years.
What is BIIB's earnings growth rate?
BIIB compound annual EPS growth rates (CAGR): 1-Year: -21.1%, 3-Year: -24.9%, 5-Year: -18.7%, 10-Year: -5.4%. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 1989 to 2025.
What are BIIB's profit margins?
Biogen Inc. net profit margin is +13.2%, operating margin is +19.1%, and gross margin is +70.5%. Margins are within a typical range for the sector. Return on Equity is +7.4%.
Is BIIB growing earnings?
BIIB earnings are declining — EPS fell -21.1% year-over-year. TTM net income dropped to $1.4B. This contrasts with the 5-year CAGR of -18.7%.
What was BIIB's best earnings year?
Biogen Inc.'s highest annual net income on record is $5.9B, achieved in fiscal year 2019. Earnings history on this page spans 1989 to 2025 and includes all annual and quarterly figures.
What were BIIB's earnings last quarter?
BIIB's most recent reported quarter was Q1 2026. Net income was $320M with diluted EPS of $2.15. For a full breakdown of all quarters, see the quarterly earnings table on this page.